CHICAGO, December 19, 2018 /PRNewswire/ --
According to the new market research report"Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 481 million by 2023 from an estimated USD 313 million in 2018, at a CAGR of 8.9%.
(Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )
Don't miss out on business opportunities in Custom Antibody Market.
The major factors driving the growth of this market are an increase in research activity-especially in the life sciences industry-along with growing industry-academia collaborations are the primary growth drivers for this market. In addition, the objective behind custom antibody production is to acquire an antibody that performs well in a particular qualitative or quantitative immunodetection method. The quality of catalog antibodies (to ensure reproducibility of results) is also an area of concern in this market, which is primarily why end users prefer custom-made antibodies.
By service, the antibody development segment is expected to account for the largest share of the Custom Antibody Market
Based on service, the Custom Antibody Market is segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody development services segment is estimated to account for the largest market share in 2018. The large share of this segment can be attributed to the increasing focus of researchers on high-quality antibodies for reproducibility, which can be hampered by using commercially available antibodies. The antibody development segment is further subsegmented into antigen preparation, immunization & hybridoma production, and antibody characterization.
Browse in-depth TOC on "Custom Antibody Market"
143 - Tables
36 - Figures
198 - Pages
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=164328301
On the basis of type, the monoclonal antibodies segment is expected to account for the largest share of the Custom Antibody Market in 2018
Custom antibodies are categorized by type as monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and other custom antibodies. The monoclonal antibodies segment is estimated to account for the largest market share in 2018. This is because monoclonal antibodies provide high specificity and selectivity and ease of production as compared to other antibodies, and are thus the preferred choice in all types of research studies. However, increasing recognition of recombinant antibodies as potential alternatives may hamper the growth of this segment to a certain extent.
North America to dominate the Custom Antibody Market during the forecast period
North America is expected to account for the largest share of the Custom Antibody Market in 2018, followed by Europe. The dominance of the North American region can be attributed to the increasing investments in the development of structure-based drug designs, growing research in the fields of genomics and proteomics, rising demand for high-quality research tools for data reproducibility, increasing focus on developing antibody-based therapeutics, and the presence of a large number of global players in this region.
Inquiry Before Buying:
https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=164328301
The prominent players in the Custom Antibody Market are Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck Group (Germany), Abcam plc (UK), Cell Signaling Technology, Inc. (US), Agilent Technologies, Inc. (US), GenScript (US), BioLegend, Inc. (US), Rockland Immunochemicals (US), ProMab Biotechnologies (US), Innovagen AB (Sweden), and ProteoGenix (US).
Browse Adjacent Markets @ Biotechnology Market Research Reports & Consulting
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/custom-antibody-market.asp
Visit Our Website: https://www.marketsandmarkets.com
SOURCE MarketsandMarkets
Share this article